伊班磷酸钠治疗恶性肿瘤骨转移性骨痛的临床研究

目的:评价伊班磷酸钠治疗恶性肿瘤骨转移引起的骨痛及其不良反应.方法:将18例恶性肿瘤骨转移骨痛的患者,采用随机、阳性对照方法,随机分为治疗组(组A,n=8)用伊班磷酸钠4 mg,阳性对照组(组B,n=10)用帕米磷酸二钠90 mg,均单次iv滴注,观察21 d评价止痛效果.结果:18例入组患者,均可评价疗效和不良反应.组A患者,有效率4/8;组B患者,有效率3/10.组A 4例有效患者,3～6(平均4.5)d起效,观察期间均无复发;组B 3例有效患者,6～9(平均7.5)d起效,2例于治疗后11～14(平均12.5)d复发.不良反应组B为发热,组A主要是恶心呕吐、骨肌肉疼痛、水肿和手足麻木等,但发生率较低,程度均轻.结论:伊班磷酸钠对恶性肿瘤骨转移所引起的骨痛具有一定的治疗作用,耐受性良好.

Clinical study of ibandronate in relieving bone-pain in malignant tumour patients with bone metastasis

AIM: To evaluate the efficacy of Ibandronate in relieving bone pain and the tolerability in malignant tumor patients with bone metastases. METHODS: By using randomized and positive control method, Ibandronate 4 mg and Pamidronate 90 mg were intravenously given once daily to patients with bone metastasized bone pain (group A, n =8) and patients in positive control group (group B, n =10), respectively. A twenty one day observation was performed. RESULTS: Four of 8 patients in group A and 3 of 10 in group B were found to have their pain relieved. No relapsed case was found in group A, while two relapsed cases were found in group B approximately 12.5 d after the treatment. The side effects were mainly nausea, myalgia, edema and numb hands and feet in both group A and group B. CONCLUSION: Ibandronate is effective in bone pain relief and is well tolerated in malignant tumor patients with bone metastases.